INSULIN-LIKE GROWTH FACTOR ACTION IN BREAST CANCER CELLS
Project Number5R01CA058706-02
Contact PI/Project LeaderROSEN, NEAL
Awardee OrganizationSLOAN-KETTERING INST CAN RESEARCH
Description
Abstract Text
The goals of the proposal are the investigation of the role played by
insulin-like growth factors (IGFs) in the biology of human breast cancer
and of the mechanism by which these factors stimulate mitogenesis in this
system. the long term aim is to use these studies to define the
biochemical events underlying tumor progression in this disease and to
identify new targets for therapeutic intervention. Previous work has
shown that IGF-I and IGF-II elicit a marked mitogenic response in some
breast cancer cell lines by binding to the IGF-I receptor. Moreover,
overexpression of IGF-II in an estrogen-dependent cell line confers some
aspects of estrogen independence. In addition, stromal cells in breast
tumors express IGF-II, whereas tumor cells do in only a minority of
cases. Taken together, the data imply that IGFs are potential paracrine
regulators of breast tumor cell growth and that expression of IGF-II by
the tumor cell may be an event in tumor progression that allows the cell
to become independent of stromal factors.
The current proposal aims to define the effects of IGFs on breast cancer
cell growth in more detail, exploring the interactions of IGFs with
hormonal agents and retinoic acid and correlating growth effects with
IGF-I receptor expression, tyrosine kinase activity and
autophosphorylation. The system will be then used as a model with which
to study the mechanistic details of the transduction of the proliferative
signal by IGFs. Preliminary results reveal that IGFs activate the IGF-I
receptor tyrosine kinase with subsequent phosphorylation of its beta-
subunit and several other substrates, including pp185 (IRS1), GAP, and
GAP-associated pp62. Current studies focus on further defining these
events and in identifying their functional consequences. Interactions
of pp185 and GAP with other proteins will be characterized and assessed
in IGF-responsive and unresponsive cell lines, IGF-II transfectants, and
cells treated with antiestrogens and differentiation agents. Specific
events and interactions will be correlated with aspects of the
proliferative and transformed phenotype. Transfections with GAP
expression vectors will be performed to evaluate the role of the GAP-ras
complex in mediating these events.
No Sub Projects information available for 5R01CA058706-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA058706-02
Patents
No Patents information available for 5R01CA058706-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA058706-02
Clinical Studies
No Clinical Studies information available for 5R01CA058706-02
News and More
Related News Releases
No news release information available for 5R01CA058706-02
History
No Historical information available for 5R01CA058706-02
Similar Projects
No Similar Projects information available for 5R01CA058706-02